内镜减重与代谢治疗对非酒精性脂肪性肝病影响的系统评价与荟萃分析
该系统评价与荟萃分析纳入18项研究共863例患者,评估FDA批准的内镜减重与代谢治疗(EBMT)对非酒精性脂肪性肝病(NAFLD)的影响。
核心结论
- EBMT对治疗NAFLD有效,可显著改善肝纤维化。
- 鉴于NAFLD流行加剧及现有治疗局限,EBMT应作为潜在治疗选择进一步研究。
研究设计与样本
- 纳入18项研究共863例患者,评估EBMT后肝脏结局变化。
- 采用GRADE方法评估证据质量。
主要发现
- 6个月随访时平均体重减轻为初始体重的14.5%。
关键数值与推荐
- 主要结局为肝纤维化,证据质量低至极低。
- 次要结局包括肝功能、脂肪变、NAFLD组织学变化和胰岛素敏感性。
临床怎么用
- EBMT可作为NAFLD肥胖患者的潜在治疗选择,但需进一步研究验证。
局限性
- 主要结局的总体证据质量低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Weight loss via lifestyle intervention remains the mainstay of treatment for nonalcoholic fatty liver disease (NAFLD). Endoscopic bariatric and metabolic therapies (EBMTs) have recently been developed as an alternative treatment option for obesity. This study aimed to assess the effect of FDA-approved EBMTs on NAFLD. METHODS: We searched MEDLINE, EMBASE, Web of Science and Cochrane Central through December 2020 for studies that assessed changes in liver outcomes following EBMT. Primary Outcomes: Liver fibrosis. SECONDARY OUTCOMES: Liver biochemistry, steatosis, NAFLD histological changes and insulin sensitivity. The Grading of Recommendations, Assessment, Development, and Evidence (GRADE) approach was conducted to assess quality of evidence. RESULTS: Of 4994 potential studies, 18 studies with 863 patients were included. Average weight loss was 14.5% of initial weight at a 6-month follow-up. Primary outcomes: Following EBMT, liver fibrosis significantly reduced by standardized mean difference (SMD) of 0.7 (95% CI, 0.1, 1.3; P = .02). SECONDARY OUTCOMES: There were significant improvements in other NAFLD surrogates including alanine aminotransferase (-9.0 U/L; 95% CI, -11.6, -6.4; P < .0001), hepatic steatosis (SMD: -1.0; 95% CI, -1.2, -0.8; P < .0001) and histologic NAFLD activity score (-2.50; 95% CI, -3.5, -1.5; P < .0001). Other metabolic parameters including insulin resistance and waist circumference also significantly improved. The overall quality of the evidence for primary outcomes was low to very low. CONCLUSIONS: EBMTs appear effective at treating NAFLD with significant improvement in liver fibrosis. Given the worsening NAFLD pandemic and limitations of currently available therapies, EBMTs should be further investigated as a potential treatment option for this patient population.
引用
- Jirapinyo P, McCarty TR, Dolan RD, et al. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021. PMID: 33727164. doi:10.1016/j.cgh.2021.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。